Protalix Biotherapeutics Inc (PLX) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.61x

Protalix Biotherapeutics Inc (PLX) has a Cash Flow Reinvestment Rate of 0.61x as of December 2025, reinvesting $1.24 Million (capex $1.24 Million ) from operating cash flow of $2.03 Million. Check PLX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.61x
(Capex + Investments) / Operating CF

Total Reinvested

$1.24 Million
Capex + Investments

Operating Cash Flow

$2.03 Million
USD

Capital Expenditures

$1.24 Million
USD

Protalix Biotherapeutics Inc Cash Flow Reinvestment Rate (2009–2024)

Historical reinvestment intensity for Protalix Biotherapeutics Inc across 3 annual periods. Explore PLX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Protalix Biotherapeutics Inc (2009–2024)

Year-by-year capital reinvestment analysis for Protalix Biotherapeutics Inc. For live market cap and broader valuation context, see Protalix Biotherapeutics Inc market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 0.63x $5.50 Million $8.67 Million $1.28 Million ▼ -80.5%
2012 3.26x $2.07 Million $635.00K $2.07 Million ▲ +2236.8%
2009 0.14x $6.20 Million $44.45 Million $6.20 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow